October 18, 2016 | For more than a decade, U.S. Food & Drug Administration (FDA) and European Medicines Agency (EMA) scientists have been working together to help solve some of the world's biggest health challenges. The two organizations work collaboratively in groups called "clusters." The FDA has recently announced a new cluster that will work to advance treatments for patients with rare diseases. This cluster's primary goal is for FDA and EMA scientists to share valuable information about their work and to collaborate on certain review aspects of rare disease drug development programs. FDA Blog